论文部分内容阅读
背景与目的:目前尿路移行细胞肿瘤缺乏有效的无创监测方法。近年来发现的核基质蛋白22(nuclearmatrixprotein22,NMP22)能有效地诊断膀胱移行细胞癌。本研究探讨NMP22作为一个新的尿液中的肿瘤标志物在尿路移行细胞癌筛选诊断中的意义及其影响因素。方法:采用酶联免疫吸附试验NMP22试剂盒,对包括29例尿路移行细胞癌在内的87例泌尿系疾病患者尿液进行的NMP22测定。有尿路感染的患者排除在外。结果:以>10u/ml为阳性判断标准,NMP22对尿路移行细胞癌的敏感性和特异性分别为86.2%和94.3%(以泌尿系良性疾病作对照),远优于尿细胞学检查(86.2%vs42.3%,P<0.001)。引起假阳性的主要因素有尿路感染、泌尿系其他恶性肿瘤、肠道膀胱和肾结石等。结论:尿NMP22是一个较好的肿瘤标志物,可以替代尿液细胞学检查成为尿路移行细胞癌诊断的良好指标。
BACKGROUND & OBJECTIVE: Currently, there is a lack of effective noninvasive monitoring of urothelial cells. In recent years, the discovery of nuclear matrix protein 22 (NMP22) can effectively diagnose bladder transitional cell carcinoma. This study was to investigate the significance and influencing factors of NMP22 as a new tumor marker in urinary tract cancer screening. Methods: NMP22 was measured in urine of 87 patients with urinary tract diseases including 29 cases of urinary tract transitional cell carcinoma by enzyme-linked immunosorbent assay NMP22 kit. Patients with urinary tract infections are excluded. Results: The sensitivity and specificity of NMP22 for urothelial carcinoma were 86.2% and 94.3% respectively (judged by urological benign disease), which was much better than urinary cytology 86.2% vs42.3%, P <0.001). The main factors causing false positives are urinary tract infections, other urological malignancies, intestinal and kidney stones and bladder stones. Conclusion: Urinary NMP22 is a good tumor marker, which can replace urinary cytology as a good indicator of the diagnosis of urinary transitional cell carcinoma.